Skin cancer
Our latest articles

What are the most common biomarkers and genetic mutations in skin cancer?
Understanding the molecular aspects of skin cancer and knowing the biomarkers and genetic mutations associated with this pathology is becoming essential for clinical research and the development of more targeted and effective treatments. The genes whose mutations are currently most likely to influence skin cancer treatment are BRAF, c-KIT, and NRAS.

Learn about melanoma!
Skin cancers are mainly divided into two very distinct types: carcinomas and melanomas. More rare, melanomas represent only about 10% of skin cancer cases.
Frequently asked questions
What are the different types of skin cancers?
Skin cancers are characterized by an uncontrolled and abnormal multiplication of skin tissue (skin tissue). There are two main categories:
- carcinomas (about 90% of cases)
- melanomas (about 10% of cases)
Other types of skin cancers also exist, such as Merkel cell carcinoma, Kaposi sarcoma, and cutaneous lymphoma, but they are much less common, accounting for less than 1% of skin cancers.
What is the TNM melanoma score?
The TNM score is a classification system used to assess the stage of a cancer, plan treatment, and predict prognosis.
In melanoma, we look in particular for:
- The T, which describes the size and extent of the tumor
- The N, which indicates whether the cancer has spread to nearby lymph nodes
- The M, which indicates whether the cancer has spread to other parts of the body, called metastases
The Breslow Index is a measure of tumor thickness that is used to assess the severity of melanoma. The Breslow Index is an important element in the classification of melanoma according to the TNM classification system. More specifically, it is used to determine category T, which measures the size and extension of the tumor.
This information can be found on the pathologic report or a consultation report.
NB: On the platform Klineo, it is a simplified version of the TNM stadium. In the search fields, only the first number following the letter must be selected (ex: “Pt1c N0i+ M0” = “T1N0M0”)
TNM classification table for melanomas
Primary tumour (T)
| T | Tumour thickness |
|---|---|
| pTX | No tumour detected |
| pT0 | No evidence of primary tumour |
| pTis | Melanoma in situ (Clark level I) (atypical melanocytic hyperplasia, severe melanocytic dysplasia, no invasive malignant lesion) |
| pT1 | Tumour < 1 mm thick |
| pT1a | tumour < 0.8 mm thick without ulceration |
| pT1b | tumour < 0.8 mm thick with ulceration or tumour 0.8 mm to 1 mm thick with or without ulceration |
| pT2 | Tumour 1 to 2 mm thick |
| pT2a | without ulceration |
| pT2b | with ulceration |
| pT3 | Tumour 2 to 4 mm thick |
| T3a | without ulceration |
| T3b | with ulceration |
| pT4 | Tumour more than 4 mm thick |
| T4a | without ulceration |
| T4b | with ulceration |
Lymph nodes (N)
| N | Number of involved locoregional lymph nodes |
|---|---|
| NX | Regional lymph nodes not assessed |
| N0 | No regional lymph node involvement |
| N1 | Metastasis in one lymph node or lymphatic emboli without lymph node metastasis |
| N1a | Microscopic involvement (no clinical detection) |
| N1b | Macroscopic metastasis (clinically detectable) |
| N1c | Satellite nodule or in-transit metastasis without lymph node involvement |
| N2 | Metastasis in 2 or 3 lymph nodes or lymphatic emboli with lymph node metastases |
| N2a | Microscopic involvement only |
| N2b | Macroscopic involvement |
| N2c | Satellite nodule(s) or in-transit metastasis(es) with only 1 lymph node involved |
| N3 | 4 or more lymph node metastases, or metastatic lymph node conglomerate, or satellite nodules or in-transit metastases with 2 or more lymph node metastases |
| N3a | Microscopic involvement only |
| N3b | Macroscopic involvement |
| N3c | Satellite nodules or in-transit metastases with 2 or more lymph node metastases |
Distant metastases (M)
| M | Site |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastases |
| M1a | Cutaneous, subcutaneous tissue or lymph node metastases beyond the drainage area |
| M1b | Pulmonary metastases |
| M1c | Any other visceral involvement other than the central nervous system |
| M1d | Metastases in the central nervous system |
How are Merkel carcinomas treated?
At the localized stadium : surgery is the main treatment, followed by radiation therapy. Adjuvant chemotherapy may be combined with surgery and radiation therapy.
In the metastatic stage : Immunotherapy treatment may be proposed (anti-PDL1). The alternative to this treatment may be chemotherapy with carboplatin-etoposide.
Surgery : Surgery is the main treatment for Merkel carcinomas. Different surgical techniques can be used depending on size, location and medical history (surgical excision, Mohs surgery, lymph node dissection...)
Radiotherapy : Radiotherapy consists in using radiation (we also say rays or radiation) to destroy cancer cells by blocking their ability to multiply. We are talking about a locoregional treatment of cancers. In the case of Merkel carcinomas, radiation therapy may also be prescribed after surgery, this is called adjuvant therapy.
Chemotherapy : This is a treatment that uses powerful drugs to destroy cancer cells by preventing them from multiplying or spreading in the body. In the case of Merkel carcinomas, the most common chemotherapies are:
- Cisplatin (Platinol AQ) or carboplatin (Paraplatin, Paraplatin AQ), which can be combined with etoposide (Vepesid, VP-16). Only topotecan (Hycamtin) may be used in some cases.
Immunotherapy: Immunotherapy is a treatment that aims to stimulate the body’s immune defenses against cancer cells. In the case of Merkel carcinomas, anti-PDL1 antibodies, such as Avelumab (BAVENCIO), may be used in some cases.
There are other treatments available via clinical trials. With Klineo, you can find the clinical trials that suit your situation. For this, it is important to enter the treatments received in order to find relevant clinical trials. This information can be found in the recent consultation report.
Patient associations

France Asso Cancer et Peau
Prevention - Support - Research for skin cancers
Discover this association →
Gynaecological cancer
Pancreatic cancer
Paediatrics
Kidney cancer
Leukemia